ID   NUCB2_RAT               Reviewed;         420 AA.
AC   Q9JI85;
DT   02-NOV-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   02-OCT-2024, entry version 142.
DE   RecName: Full=Nucleobindin-2;
DE   AltName: Full=DNA-binding protein NEFA;
DE   AltName: Full=Prepronesfatin;
DE   Contains:
DE     RecName: Full=Nesfatin-1;
DE   Flags: Precursor;
GN   Name=Nucb2; Synonyms=Nefa;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Ovary;
RA   Hirschfeld G., Heiden I., Barnikol-Watanabe S., Barnikol H.U.,
RA   Hilschmann N.;
RT   "Rat NEFA mRNA.";
RL   Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Hauge X., Neve K.A.;
RT   "Characterization of rat NEFA protein.";
RL   Submitted (FEB-2000) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Prostate;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   FUNCTION OF NESFATIN.
RX   PubMed=17036007; DOI=10.1038/nature05162;
RA   Oh-I S., Shimizu H., Satoh T., Okada S., Adachi S., Inoue K., Eguchi H.,
RA   Yamamoto M., Imaki T., Hashimoto K., Tsuchiya T., Monden T., Horiguchi K.,
RA   Yamada M., Mori M.;
RT   "Identification of nesfatin-1 as a satiety molecule in the hypothalamus.";
RL   Nature 443:709-712(2006).
RN   [5]
RP   FUNCTION, INTERACTION WITH GNAI3, GBA MOTIF, AND MUTAGENESIS OF LEU-315;
RP   PHE-318 AND LEU-319.
RX   PubMed=21653697; DOI=10.1074/jbc.m110.204099;
RA   Garcia-Marcos M., Kietrsunthorn P.S., Wang H., Ghosh P., Farquhar M.G.;
RT   "G Protein binding sites on Calnuc (nucleobindin 1) and NUCB2 (nucleobindin
RT   2) define a new class of G(alpha)i-regulatory motifs.";
RL   J. Biol. Chem. 286:28138-28149(2011).
RN   [6]
RP   FUNCTION OF NESFATIN.
RX   PubMed=22293188; DOI=10.1016/j.bbrc.2012.01.076;
RA   Yamawaki H., Takahashi M., Mukohda M., Morita T., Okada M., Hara Y.;
RT   "A novel adipocytokine, nesfatin-1 modulates peripheral arterial
RT   contractility and blood pressure in rats.";
RL   Biochem. Biophys. Res. Commun. 418:676-681(2012).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-332, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
CC   -!- FUNCTION: Calcium-binding protein which may have a role in calcium
CC       homeostasis (By similarity). Acts as a non-receptor guanine nucleotide
CC       exchange factor which binds to and activates guanine nucleotide-binding
CC       protein (G-protein) alpha subunit GNAI3 (PubMed:21653697).
CC       {ECO:0000250|UniProtKB:P81117, ECO:0000269|PubMed:21653697}.
CC   -!- FUNCTION: [Nesfatin-1]: Anorexigenic peptide, seems to play an
CC       important role in hypothalamic pathways regulating food intake and
CC       energy homeostasis, acting in a leptin-independent manner. May also
CC       exert hypertensive roles and modulate blood pressure through directly
CC       acting on peripheral arterial resistance. {ECO:0000269|PubMed:17036007,
CC       ECO:0000269|PubMed:22293188}.
CC   -!- SUBUNIT: Interacts (via GBA motif) with guanine nucleotide-binding
CC       protein G(i) alpha subunit GNAI3 (PubMed:21653697). Preferentially
CC       interacts with inactive rather than active GNAI3 (PubMed:21653697).
CC       Interaction with GNAI3 is inhibited when NUCB2 binds calcium, probably
CC       due to a conformational change which renders the GBA motif inaccessible
CC       (PubMed:21653697). Binds to the postmitotic growth suppressor NDN;
CC       coexpression abolishes NUCB2 secretion (By similarity).
CC       {ECO:0000250|UniProtKB:P81117, ECO:0000269|PubMed:21653697}.
CC   -!- SUBCELLULAR LOCATION: Golgi apparatus {ECO:0000250}. Endoplasmic
CC       reticulum {ECO:0000250}. Nucleus envelope {ECO:0000250}. Membrane
CC       {ECO:0000250}; Peripheral membrane protein {ECO:0000250}. Cytoplasm
CC       {ECO:0000250}. Secreted {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: [Nesfatin-1]: Secreted.
CC   -!- DOMAIN: The GBA (G-alpha binding and activating) motif mediates binding
CC       to the alpha subunits of guanine nucleotide-binding proteins (G
CC       proteins). {ECO:0000269|PubMed:21653697}.
CC   -!- MISCELLANEOUS: NEFA stands for N=DNA-binding; EF=EF-hand; A=Acidic
CC       region.
CC   -!- SIMILARITY: Belongs to the nucleobindin family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF250142; AAF75993.1; -; mRNA.
DR   EMBL; AF238223; AAK66864.1; -; mRNA.
DR   EMBL; BC061778; AAH61778.1; -; mRNA.
DR   RefSeq; NP_067695.1; NM_021663.2.
DR   AlphaFoldDB; Q9JI85; -.
DR   SMR; Q9JI85; -.
DR   IntAct; Q9JI85; 2.
DR   STRING; 10116.ENSRNOP00000027753; -.
DR   iPTMnet; Q9JI85; -.
DR   PhosphoSitePlus; Q9JI85; -.
DR   jPOST; Q9JI85; -.
DR   PaxDb; 10116-ENSRNOP00000027753; -.
DR   Ensembl; ENSRNOT00055011151; ENSRNOP00055008730; ENSRNOG00055006787.
DR   Ensembl; ENSRNOT00060030920; ENSRNOP00060025035; ENSRNOG00060017872.
DR   Ensembl; ENSRNOT00065050545; ENSRNOP00065041535; ENSRNOG00065029150.
DR   GeneID; 59295; -.
DR   KEGG; rno:59295; -.
DR   UCSC; RGD:620888; rat.
DR   AGR; RGD:620888; -.
DR   CTD; 4925; -.
DR   RGD; 620888; Nucb2.
DR   eggNOG; KOG3866; Eukaryota.
DR   InParanoid; Q9JI85; -.
DR   OrthoDB; 2881246at2759; -.
DR   PhylomeDB; Q9JI85; -.
DR   PRO; PR:Q9JI85; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0005737; C:cytoplasm; ISO:RGD.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISO:RGD.
DR   GO; GO:0005793; C:endoplasmic reticulum-Golgi intermediate compartment; ISO:RGD.
DR   GO; GO:0005615; C:extracellular space; IDA:RGD.
DR   GO; GO:0005797; C:Golgi medial cisterna; IDA:RGD.
DR   GO; GO:0005640; C:nuclear outer membrane; ISO:RGD.
DR   GO; GO:0005634; C:nucleus; ISO:RGD.
DR   GO; GO:0005509; F:calcium ion binding; ISO:RGD.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0001965; F:G-protein alpha-subunit binding; IDA:UniProtKB.
DR   GO; GO:0005085; F:guanyl-nucleotide exchange factor activity; IDA:UniProtKB.
DR   GO; GO:0005164; F:tumor necrosis factor receptor binding; IPI:RGD.
DR   GO; GO:1901142; P:insulin metabolic process; IDA:RGD.
DR   GO; GO:0032099; P:negative regulation of appetite; IMP:RGD.
DR   GO; GO:0043951; P:negative regulation of cAMP-mediated signaling; IDA:RGD.
DR   GO; GO:0045599; P:negative regulation of fat cell differentiation; IDA:RGD.
DR   GO; GO:0070093; P:negative regulation of glucagon secretion; IDA:RGD.
DR   GO; GO:0046627; P:negative regulation of insulin receptor signaling pathway; IDA:RGD.
DR   GO; GO:0046321; P:positive regulation of fatty acid oxidation; IDA:RGD.
DR   GO; GO:2000845; P:positive regulation of testosterone secretion; IDA:RGD.
DR   GO; GO:0009749; P:response to glucose; IEP:RGD.
DR   GO; GO:0044752; P:response to human chorionic gonadotropin; IEP:RGD.
DR   GO; GO:1990680; P:response to melanocyte-stimulating hormone; IEP:RGD.
DR   GO; GO:0042594; P:response to starvation; IEP:RGD.
DR   GO; GO:0051238; P:sequestering of metal ion; ISO:RGD.
DR   GO; GO:0007264; P:small GTPase-mediated signal transduction; IDA:UniProtKB.
DR   Gene3D; 1.10.238.10; EF-hand; 1.
DR   InterPro; IPR011992; EF-hand-dom_pair.
DR   InterPro; IPR018247; EF_Hand_1_Ca_BS.
DR   InterPro; IPR002048; EF_hand_dom.
DR   InterPro; IPR040250; Nucleobindin.
DR   PANTHER; PTHR19237; NUCLEOBINDIN; 1.
DR   PANTHER; PTHR19237:SF22; NUCLEOBINDIN-2; 1.
DR   Pfam; PF13499; EF-hand_7; 1.
DR   SMART; SM00054; EFh; 2.
DR   SUPFAM; SSF47473; EF-hand; 1.
DR   PROSITE; PS00018; EF_HAND_1; 2.
DR   PROSITE; PS50222; EF_HAND_2; 2.
PE   1: Evidence at protein level;
KW   Calcium; Cleavage on pair of basic residues; Cytoplasm; DNA-binding;
KW   Endoplasmic reticulum; Golgi apparatus;
KW   Guanine-nucleotide releasing factor; Membrane; Metal-binding; Nucleus;
KW   Phosphoprotein; Reference proteome; Repeat; Secreted; Signal.
FT   SIGNAL          1..24
FT                   /evidence="ECO:0000255"
FT   CHAIN           25..420
FT                   /note="Nucleobindin-2"
FT                   /id="PRO_0000004167"
FT   CHAIN           25..106
FT                   /note="Nesfatin-1"
FT                   /id="PRO_0000419821"
FT   DOMAIN          241..276
FT                   /note="EF-hand 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   DOMAIN          293..328
FT                   /note="EF-hand 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   DNA_BIND        171..223
FT                   /evidence="ECO:0000250"
FT   REGION          194..225
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          213..420
FT                   /note="Binds to necdin"
FT                   /evidence="ECO:0000250"
FT   REGION          366..420
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           304..334
FT                   /note="GBA"
FT                   /evidence="ECO:0000250|UniProtKB:P80303"
FT   COMPBIAS        366..386
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        387..402
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         254
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   BINDING         256
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   BINDING         258
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   BINDING         265
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   BINDING         306
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   BINDING         308
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   BINDING         310
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   BINDING         317
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   MOD_RES         332
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MUTAGEN         315
FT                   /note="L->A: Abolishes binding to and activation of GNAI3;
FT                   when associated with A-319."
FT                   /evidence="ECO:0000269|PubMed:21653697"
FT   MUTAGEN         318
FT                   /note="F->A: Abolishes binding to and activation of GNAI3."
FT                   /evidence="ECO:0000269|PubMed:21653697"
FT   MUTAGEN         319
FT                   /note="L->A: Abolishes binding to and activation of GNAI3;
FT                   when associated with A-315."
FT                   /evidence="ECO:0000269|PubMed:21653697"
FT   CONFLICT        38
FT                   /note="E -> D (in Ref. 2; AAK66864)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        352
FT                   /note="S -> G (in Ref. 2; AAK66864)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   420 AA;  50090 MW;  E7684E6C835F98FB CRC64;
     MRWRTIQARY CFLLVPCVLT ALEAVPIDVD KTKVHNVEPV ESARIEPPDT GLYYDEYLKQ
     VIEVLETDPH FREKLQKADI EEIRSGRLSQ ELDLVSHKVR TRLDELKRQE VGRLRMLIKA
     KLDALQDTGM NHHLLLKQFE HLNHQNPDTF ESKDLDMLIK AATADLEQYD RTRHEEFKKY
     EMMKEHERRE YLKTLSEEKR KEEEAKFAEM KRKHEDHPKV NHPGSKDQLK EVWEETDGLD
     PNDFDPKTFF KLHDVNNDGF LDEQELEALF TKELDKVYNP QNAEDDMIEM EEERLRMREH
     VMNEIDNNKD RLVTLEEFLR ATEKKEFLEP DSWETLDQQQ LFTEEELKEY ESIIAIQESE
     LKKKADELQK QKEELQRQHD HLEAQKQEYQ QAVQQLEQKK FQQGIAPSGP AGELKFEPHT
//
